Search Results for anti-TNF

Showing 1 – 3

Biosimilars in the EU: New IMS Report Shows Savings Through Competition By Zachary Brennan - Published 09 May 2017

A new report released Tuesday, prepared by QuintilesIMS at the request of the European Commission, found EU countries are saving lots of money from biosimilars even if market share is low.

Categories: News, Europe, EC, EMA, Biologics and biotechnology, Government affairs, Regulatory intelligence, Regulatory strategy, Reimbursement

Tags: biosimilars, biologic competition, anti-TNF, HGH

Biosimilars in the EU: Lower Costs, Increased Patient Access, IMS Report Finds By Zachary Brennan - Published 20 June 2016

For those tracking the contentious debate over drug and biologic price hikes in the US, an IMS Health report released on Monday offers the latest evidence yet that a robust biosimilars market can not only lower prices across drug classes but also increase patient uptake of such treatments.

Categories: News, Europe, EC, EMA, MHRA, Biologics and biotechnology, Due Diligence, Government affairs, Postmarket surveillance, Quality, Research and development

Tags: biosimilars, EU uptake of biosimilar medicinal products, IMS Health, EPO, Anti-TNF, Humira, Enbrel, Remicade

European Commission Clears First Enbrel Biosimilar Ahead of US By Zachary Brennan - Published 18 January 2016

The European Commission over the weekend signed off on the first biosimilar for Amgen’s blockbuster rheumatoid arthritis treatment Enbrel, a version of which is also making its way through a separate review by the US Food and Drug Administration (FDA).

Categories: News, Asia, Europe, US, EC, EMA, FDA, MFDS, Clinical, Due Diligence, Submission and registration

Tags: Enbrel, anti-TNF, MFDS, Amgen patents